Global Veterinary Pain Management Market Size, Share & Industry Trends Analysis Report By Animal type (Livestock Animal and Companion Animal), By End-Use, By Indication, By Product, By Regional Outlook and Forecast, 2023 - 2030

Global Veterinary Pain Management Market Size, Share & Industry Trends Analysis Report By Animal type (Livestock Animal and Companion Animal), By End-Use, By Indication, By Product, By Regional Outlook and Forecast, 2023 - 2030

The Global Veterinary Pain Management Market size is expected to reach $2.5 billion by 2030, rising at a market growth of 6.2% CAGR during the forecast period.

Obesity is the primary cause of joint issues in dogs, and it can also contribute to other orthopedic problems like hip dysplasia and arthritis pain. Thus, the Companion segment will register a 2/5th share of the market by 2030. Due to the additional pressure on bones, obesity in pet companions can cause various diseases of the bones and joints. In fatty and overweight animals, arthritis and ligament rips are prevalent and more severe. Compared to adult dogs, puppies are quite more prone to fractures. Additionally, the owner's capacity to spend on their pet's orthopedic operation and growing pet care awareness are fostering the market's expansion. Some of the factors impacting the market are increasing public concern for animal health and welfare, humanization trend and rising pet ownership, and legal issues in pain management.

The demand for these products has increased as a result of the increasing efforts taken by various governments in different areas. In the UK, pertinent cattle health and welfare issues tend to be resolved through the Cow Health and Welfare Group (CHAWG). The CHAWG is the first contact for inquiries relating to the welfare, health, and disease concerns currently impacting cattle. The makeup of CHAWG was a highly beneficial resource for the market because it offered a broad and in-depth range of information about cattle health and welfare. Therefore, this market is being driven by a rising number of initiatives undertaken by major businesses and government agencies. Globally, pet ownership is on the rise, especially in millennial households, inclined to be smaller families with children raised later in life. Pet lovers benefit the business and are anticipated to significantly contribute to market expansion during the forecast period. Many businesses are striving to provide superior pet care products in response to the rising demand for luxury pet products worldwide to acquire a significant share of the market. Given these factors, it is projected that as pet ownership and the humanization phenomenon increase, this will impact the market.

However, there are several ethical and practical issues in treating farm animals' pain. The conflicting needs of society as a whole and animals are apparent in a legal sense. Legislative frameworks for the administration of analgesic drugs to these animals need to consider various factors, such as the risk of abuse if powerful controlled analgesic drugs, like narcotics, are not properly stored and accounted for. Thus, the legal issues surrounding pain management could have a negative effect on the market's expansion in the coming years.

Animal type Outlook

By animal type, the market is classified into livestock animal and companion animal. The companion animal covered a considerable revenue share in the market in 2022. Their increased ownership, awareness, and need for effective animal care are responsible for the growth of the segment. Additionally, the incidence of obesity and other chronic diseases like cancer and osteoarthritis is rising, fueling the market.

End-Use Outlook

Based on end-use, the market is categorized into hospitals & clinics and others. In 2022, the hospitals and clinics segment witnessed the largest revenue share in the market. It is due to these verticals provide a wide range of diagnostic and treatment options. The need for outpatient facilities and increased surgical procedures are major growth drivers propelling the segment's expansion. Additionally, veterinary hospitals have modern technology.

Indication Outlook

On the basis of indication, the market is fragmented into osteoarthritis, post-operative pain, and others. The post-operative pain recorded a remarkable revenue share in the market in 2022. The growing number of veterinary surgeries in both developed and developing markets can be attributed to the significant proportion of this segment. The demand for veterinary surgery is driven by an increase in the prevalence of periodontal disease in pets and a need for better treatment alternatives. Most animals experience pain after surgery, prompting the use of veterinary pain management products.

Product Outlook

Based on product, the market is segmented into NSAIDs, anesthetics, opioids, and others. In 2022, the NSAIDs segment dominated the market with the maximum revenue share. This is due to the increased use of nonsteroidal anti-inflammatory drugs (NSAIDs) for animal analgesics. NSAIDs are widely used to relieve pain and inflammation in animals with osteoarthritis. The major market players are also creating brand-new NSAIDs to reduce the reactions and negative effects brought on by existing ones. Animal owners are under increasing pressure to adhere to the prevailing veterinarian health standards to meet consumer demand for dairy products, fresh meat, and dietary supplements generated from animals. The use of veterinary NSAIDs is anticipated to increase in the coming years.

Regional Outlook

Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region generated the highest revenue share in the market. This is due to an increase in pet ownership and the need for superior animal care. Well-established and cutting-edge animal healthcare facilities are also supporting the growth. The requirement for veterinary prescriptions in North America is anticipated to increase prescription drug sales during the forecasted period in this region.

The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, Bayer AG, Zoetis, Inc., Merck & Co., Inc., Elanco Animal Health, Inc., Zomedica Corp. (Assisi Animal Health), Norbrook Laboratories Limited, Ceva Santé Animale, Dechra Pharmaceuticals PLC, and Vetoquinol SA (Soparfin SCA)

Strategy Deployed in Veterinary Pain Management Market

May-2023: Zoetis, Inc. got approval from the U.S. Food and Drug Administration (FDA) for Librela, an anti-NGF monoclonal antibody treatment for canine OA pain, is both safe and effective in reducing symptoms of the condition over the long term in dogs.

Sep-2022: Zoetis, Inc. completed the acquisition of NewMetrica, a company that offers scientifically validated tools to assess animal welfare. Through this acquisition, Zoetis would be better equipped to provide care along the entire continuum, increase knowledge of quality-of-life evaluations, and gain a deeper understanding of an animal's wellbeing.

Jun-2022: Zoetis, Inc. announced the acquisition of Basepaws, a company that develops early-warning health risk diagnostics for pets using genetic and microbiome information. With the addition of Basepaws, Zoetis would further bolster its line-up of solutions for precise animal health across genetics, diagnostics, and data analytics for domestic animals as well as farm animals.

Jan-2022: Zoetis, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Solensia, an antibody therapy that controls the discomfort of feline osteoarthritis (OA), enhancing their mobility, comfort, and general well-being. Solensia's clearance is a significant advancement in the treatment of feline OA pain shown to manage OA discomfort and assist cats in regaining more mobility.

Jan-2022: Dechra Pharmaceuticals PLC signed an agreement to acquire Isoflurane and Sevoflurane from Halocarbon Life Sciences, a Pioneering company dedicated to developing cutting-edge medical technologies and advancing healthcare solutions. Through this acquisition, Dechra would be able to expand its portfolio, delivering quality products to the veterinary community. Moreover, these products would complement to their sedative and anesthetic range, fueling their growth in surgical solutions.

Jan-2022: Boehringer Ingelheim International GmbH came into collaboration with MabGenesis, a biopharmaceutical company that set out to create both human and animal therapeutic monoclonal antibodies. According to the agreement, MabGenesis would use its distinctive platform to find first-in-class candidate antibodies against targets of interest chosen by Boehringer Ingelheim. Moreover, the ability to create and market goods because of the agreement will belong to Boehringer Ingelheim.

Dec-2021: Elanco Animal Health, Inc. came into partnership with Morris Animal Foundation, an organization enhancing animal health through research and care. Through this partnership, would be able to create the essential tools needed for enhancing their capability to diagnose and monitor dogs affected with the conditions.

Sep-2021: Boehringer Ingelheim International GmbH signed a collaboration with Invetx, a business creating the leading animal health biotechnology innovation platform for protein-based therapies. Through this collaboration, both companies would create novel, species-specific monoclonal antibody (mAb) biotherapeutics that would initially target dogs and cats to treat a variety of veterinary species disorders.

Apr-2021: Elanco Animal Health, Inc. introduced Elura, a new CKD treatment for cats that tackles associated weight loss. Elura is a solution with an appealing taste and minimal dosage and is recommended to be initiated upon diagnosis. Moreover, this treatment can be continued over the long term, assisting pet owners in caring for their cats as they navigate the illness.

Jul-2019: Elanco Animal Health, Inc. completed the acquisition of Aratana Therapeutics, a company Pioneering pet treatments, enhancing well-being through innovative therapies for improved animal health. Through this acquisition, Aratana's robust standing in the specialized market, combined with its portfolio and upcoming projects, aligns and capabilities would be added to Elanco's pet therapy brands.

Scope of the Study

Market Segments covered in the Report:

By Animal type

• Livestock Animal
• Companion Animal

By End-Use

• Hospitals & Clinics
• Others

By Indication

• Osteoarthritis
• Post-operative pain
• Others

By Product

• NSAIDs
• Opioids
• Anesthetics
• Others

By Geography

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific
• LAMEA
• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA

Companies Profiled

• Boehringer Ingelheim International GmbH
• Bayer AG
• Zoetis, Inc.
• Merck & Co., Inc.
• Elanco Animal Health, Inc.
• Zomedica Corp. (Assisi Animal Health)
• Norbrook Laboratories Limited
• Ceva Santé Animale
• Dechra Pharmaceuticals PLC
• Vetoquinol SA (Soparfin SCA)

Unique Offerings from KBV Research

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free